

## DAFTAR PUSTAKA

1. IDF. Diabetes atlas. 8<sup>th</sup> edition. International Diabetes Federation (IDF); 2017.
2. Zheng Y, H.Ley Sylvia, B.Hu Frank. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol.* 2018;14(2): 88-98.
3. WHO. Global report on diabetes. France :WHO; 2016.
4. Kemenkes RI. Riset kesehatan dasar 2013. Jakarta: Balai Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI; 2013.
5. Dinas Kesehatan Kota Padang. Laporan tahunan tahun 2017. Padang; 2018.
6. PERKENI. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia tahun 2015. Jakarta: PB PERKENI; 2015.
7. ADA. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2010a;33 (suppl 1): S63-65.
8. ADA. Standards of medical care in diabetes. *Diabetes Care.* 2017; 40 (suppl 1): S16.
9. Goodman Gilman. Dasar farmakologi terapi. Edisi 10. Jakarta: EGC; 2007.hlm.1004.
10. Gong Li, Goswami Srijib, M.Giacomini Kathleen, B.Altman Russ, dan E.Klein Teri. Metformin pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenet Genomics.* 2012;22(11) :820-7.
11. Becker ML, Visser LE, Van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. *Pharmacogenet Genomics.* 2010;20(1):38-44.
12. Becker ML, Visser LE, Van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. *Pharmacogenomics J.* 2009;9:242-7.

13. Arimany-Nardi, H Koepsell, Pastor-Angdala. Role of SLC22A1 Polymorphic variants in drug disposition, therapeutics response, and drug-drug interactions. *Pharmacogenomics J.* 2015: 1-15
14. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. *Pharmacogenetics.* 2002; 12:591–5.
15. Perwitasari DA, Attobari J. Polymorphism of organic cation transporter 1 (OCT1) in Indonesian cancer patients. *Int J Pharm Sci.* 2014;6 (Issue 5):380-2
16. Powers AC. Diabetes mellitus: diagnosis, classification, and pathophysiology. In: Kasper, Fauci, Hauser, Longo, Jameson, Loscalzo. *Harrison's principle of internal medicine.* 19<sup>th</sup> Edition. New York: McGraw Hill Education; 2015.p.2399.
17. ADA. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2010b;33 (suppl 1): S62.
18. Powers AC. Diabetes mellitus: diagnosis, classification, and pathophysiology. In: Kasper, Fauci, Hauser, Longo, Jameson, Loscalzo. *Harrison's Principle of internal medicine* 19<sup>th</sup> Edition. New York: McGraw Hill Education. 2015.p.2401.
19. De Fronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes.* 2009;58: 773-795.
20. Bretnall AE, Clarke GS. Metformin hydrochloride. analytical profiles of drug substances and excipients. 1998;25:247.
21. Bailey CJ, Campbell IW, Chan J, Davidson JA, Howlett H, Ritz P, editors. *Metformin the gold standard a scientific handbook.* Chichester :Wiley. 2007;37.
22. Metformin. <https://www.drugbank.ca/drugs/DB00331> - diakses September 2018.
23. Powers AC, D'Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: *Goodman&gillman's. The*

- pharmacological basis of therapeutics. 12<sup>th</sup> Edition. New York: McGraw Hill Education; 2011.p.1259.
24. An Hongying, He ling. Current understanding of metformin effect on the control of hyperglycemia in diabetes. *J Endocrinol.* 2016;228:R97–R98.
  25. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. *J Hum Genet.* 2007;52:117-122.
  26. Shu Y, Sheardown SA, Brown C, Ryan P.O, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. *J Clin Invest.* 2007;117(5):1422-1431.
  27. Umamaheswaran G, Praveen RG, Damodaran SE, Das AK, Adithan C. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in south indian type 2 diabetes mellitus patients. *Clin Exp Med.* 2015; 15(4):511-7.
  28. Ismail S, Essawi M. Genetic polymorphism studies in human. *Middle East J Med Genet.* 2012; 1(2):57–63.
  29. Kennedy Martha SN. Pancreatic hormones and antidiabetic drugs. In: Katzung BG, Masters SB, Trevor AJ. *Basic & Clinical Pharmacology* 12th Edition. New York : Mc graw Hill Medical; 2012.p.757.
  30. Metformin Drug Interactions. <https://www.drugs.com/drug-interactions/metformin.html> - diakses September 2018
  31. Yuwono T. *Biologi molekuler.* Jakarta: Erlangga; 2005.
  32. Cells, genomes, dna, and genes. <https://www.ncbi.nlm.nih.gov/books/NBK115568/> - diakses Juli 2019.
  33. Brooker RJ. *Concepts of genetic.* New York : McGraw-Hill; 2012. 2
  34. Basic genetic information. <https://www.ncbi.nlm.nih.gov/books/NBK115558/> - diakses Juli 2019.
  35. Tabitha M. *Genetic basics.* US: National Institute of General Medical Sciences; 2001. 3-6.
  36. Genetic Variations. [https://www.ncbi.nlm.nih.gov/books/NBK115568/#ch1.I14\\_Genetic\\_Variation](https://www.ncbi.nlm.nih.gov/books/NBK115568/#ch1.I14_Genetic_Variation) - diakses Juli 2019.

37. What are single nucleotide polymorphisms (SNPs)?  
<https://ghr.nlm.nih.gov/primer/genomicresearch/snp-> diakses Juli 2019.
38. SLC22A1 Gene (Protein Coding). <https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC22A1> – diakses September 2018.
39. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehr D, Sabolić I, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. *Clin Pharmacol Ther.* 2009;86:299–306.
40. Gilchrist SE, Alcorn J. Lactation stage-dependent expression of transporters in rat whole mammary gland and primary mammary epithelial organoids. *Fundam Clin Pharmacol.* 2010;24:205–214.
41. Ito N, Ito K, Ikebuchi Y, Kito T, Miyata H, Toyoda Y, et al. Organic cation transporter/solute carrier family 22a is involved in drug transfer into milk in mice. *J Pharm Sci.* 2014;103:3342–8.
42. Lee N, Hebert MF, Prasad B, Easterling TR, Kelly EJ, Unadkat JD, et al. Effect of gestational age on mRNA and protein expression of polyspecific organic cation transporters during pregnancy. *Drug Metab Dispos.* 2013; 41:2225–2232.
43. Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, et al. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. *J Pharmacol Exp Ther.* 2008; 324:558–567.
44. More SS, Li S, Yee SW, Chen L, Xu Z, Jablons DM, et al. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. *Mol Cancer Ther.* 2010; 9:1058–1069.
45. Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI, Sabater M, Pardo G, Ricart W, et al. OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects. *Diabetes.* 2011;60:168–176.
46. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. *Drug Metab Pharmacokinet.* 2005; 20:452–477.

47. Zhang T, Xiang CD, Gale D, Carreiro S, Wu EY, Zhang EY, et al. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. *Drug Metab Dispos.* 2008;36:1300–7.
48. Gupta S, Wulf G, Henjakovic M, Koepsell H, Burckhardt G, Hagos Y, et al. Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. *J Pharmacol Exp Ther.* 2012; 341:16–23.
49. Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U, et al. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. *Genome Med.* 2011; 3:82.
50. Jonker JW, Schinkel AH. Pharmacological and Physiological Functions of The Polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). *J Pharmacol Exp Ther.* 2004; 308:2–9.
51. Koepsell H. Role of organic cation transporters in drug-drug interaction. *Expert Opin Drug Metab Toxicol.* 2015;11:1619–1633.
52. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. *Hepatology.* 2009; 50:1227–1240.
53. Reference SNP (refSNP) Cluster Report: rs683369. [https://www.ncbi.nlm.nih.gov/projects/SNP/snp\\_ref.cgi?rs=rs683369](https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=rs683369) – diakses September 2018.
54. NCI dictionary of genetics terms. <https://www.cancer.gov/publications/dictionaries/genetics-dictionary?expand=H> – diakses September 2018.
55. Dahlan MS. besar sampel dan cara pengambilan sampel. Edisi 3. Jakarta: Salemba Medika; 2013. 36-41.
56. PCR amplification of GFP. <https://benchling.com/protocols/GP1fQ08o/pcr-amplification-of-gfp> – diakses November 2018.

57. Matlock B. Assessment of nucleic acid purity. USA: MA, Wilmington, Thermo Fisher Scientific.2015.
58. Sur Dipanshu. A tale of genetic variation in the human SLC22A1 gene encoding OCT1 among type 2 diabetes mellitus population groups of west bengal,India.Impact Journals.2014; 2(5):97-106.
59. Al-Eitan LN, Almomani BA, Nassar AM, Elsaqa BZ, Saadeh NA. Metformin pharmacogenetics: Effects of SLC22A1, SLC22A2, SLC22A3 polymorphisms on glycemic control and HbA1c levels. J.Pers.Med.2019; 9(17): 1-11.
60. ADA. Woman and diabetes. <http://www.diabetes.org/living-with-diabetes/treatment-and-care/women/> - diakses April 2019
61. Chowdhury Anwasha, Sen Niloy, Banik Sujana. Prescribing pattern of antidiabetic drugs in type 2 diabetic patients of Noakhali City in Bangladesh. Marmara Pharm J. 2017; 21(4):1010-4.
62. Agarwal AA, Jadhav PR, Deshmukh YA. Prescribing pattern and efficacy of antidiabetic drugs in maintaining optimal glycemic levels in diabetic patients. J Basic Clin Pharm. 2014;5(3):79-83.
63. Yurgin Nicole, Secnik Kristina, Lage MJ. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther. 2007;29(2):316-325.
64. Chang HH, Hsueh YS, Cheng YW, Ou HT, Wu MH. Association between polymorphism of OCT1 and metabolic response to metformin in woman with polycystic ovarian sindrom. Int.J.Mol.Sci.2019;20(7):1720.
65. Makhtar SM, Husin A, Baba AA, Ankanthil R. Genetic variations in influx transporter gene SLC22A1 are associated with clinical response to imatinib mesylate among malaysian chronic myeloid leukemia patients.J Genet.2018.97(4):835-842.
66. Galimberti s, Bucelli C, Arrigoni E, Barate C, Grassi S, Ricci F. The hOCT1 and ABCB1 polymorphism do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget. 2017;8(50):88021-88033.

67. Rs683369 populations genetic 1000 genomes project phase 3.  
[http://www.ensembl.org/Homo\\_sapiens/Variation/Population?r=6:160129672-160130672;v=rs683369;vdb=variation;vf=104008701#1000genomesprojectphase3\\_table](http://www.ensembl.org/Homo_sapiens/Variation/Population?r=6:160129672-160130672;v=rs683369;vdb=variation;vf=104008701#1000genomesprojectphase3_table) – diakses Juli 2019

